Ocular Therapeutix
OCUL
123 hedge funds and large institutions have $176M invested in Ocular Therapeutix in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 40 increasing their positions, 36 reducing their positions, and 21 closing their positions.
148% more call options, than puts
Call options by funds: $446K | Put options by funds: $180K
11% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 36
1.03% more ownership
Funds ownership: 56.68% → 57.71% (+1%)
7% less funds holding
Funds holding: 132 → 123 (-9)
18% less capital invested
Capital invested by funds: $215M → $176M (-$39.2M)
24% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 21
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MSD Partners
New York
|
+$3.84M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.15M |
| 3 |
BS
Banco Santander
Madrid,
Spain
|
+$2.1M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$1.94M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$2.39M |
| 2 |
Millennium Management
New York
|
-$1.46M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.12M |
| 4 |
Two Sigma Advisers
New York
|
-$1.12M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.11M |
OCUL Hedge Fund Activity: Q2 2022 in Review
123 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q2 2022, worth a combined $176M — down 18% from $215M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of OCUL and 16 opened new positions — a net loss of 5 holders — while 36 trimmed existing stakes and 40 added.
The largest buyer was MSD Partners, opening a new position worth an estimated $3.84M. The largest seller was Two Sigma Investments, exiting entirely with an estimated $2.39M sold.
- 123 institutional investors held Ocular Therapeutix (OCUL) as of Q2 2022, down from 132 in Q1 2022.
- Funds reported $176M of Ocular Therapeutix stock for Q2 2022, down 18% quarter-over-quarter.
- 16 funds opened new Ocular Therapeutix positions in Q2 2022 and 21 closed out, a net change of -5 holders.
- The largest Ocular Therapeutix buyer in Q2 2022 was MSD Partners, an estimated $3.84M added.
- The largest Ocular Therapeutix seller in Q2 2022 was Two Sigma Investments, an estimated $2.39M sold.
Based on aggregated 13F filings for Q2 2022.